Cargando…

Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions

BACKGROUND: Previous studies have demonstrated that purinergic receptors could be therapeutic targets to modulate the inflammatory response in multiple models of brain diseases. However, tools for the selective and efficient targeting of these receptors are lacking. The development of new P2X7-speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilmes, Maximilian, Pinto Espinoza, Carolina, Ludewig, Peter, Stabernack, Joschi, Liesz, Arthur, Nicke, Annette, Gelderblom, Mathias, Gerloff, Christian, Falzoni, Simonetta, Tolosa, Eva, Di Virgilio, Francesco, Rissiek, Björn, Plesnilla, Nikolaus, Koch-Nolte, Friedrich, Magnus, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559872/
https://www.ncbi.nlm.nih.gov/pubmed/36224611
http://dx.doi.org/10.1186/s12974-022-02601-z
_version_ 1784807716738301952
author Wilmes, Maximilian
Pinto Espinoza, Carolina
Ludewig, Peter
Stabernack, Joschi
Liesz, Arthur
Nicke, Annette
Gelderblom, Mathias
Gerloff, Christian
Falzoni, Simonetta
Tolosa, Eva
Di Virgilio, Francesco
Rissiek, Björn
Plesnilla, Nikolaus
Koch-Nolte, Friedrich
Magnus, Tim
author_facet Wilmes, Maximilian
Pinto Espinoza, Carolina
Ludewig, Peter
Stabernack, Joschi
Liesz, Arthur
Nicke, Annette
Gelderblom, Mathias
Gerloff, Christian
Falzoni, Simonetta
Tolosa, Eva
Di Virgilio, Francesco
Rissiek, Björn
Plesnilla, Nikolaus
Koch-Nolte, Friedrich
Magnus, Tim
author_sort Wilmes, Maximilian
collection PubMed
description BACKGROUND: Previous studies have demonstrated that purinergic receptors could be therapeutic targets to modulate the inflammatory response in multiple models of brain diseases. However, tools for the selective and efficient targeting of these receptors are lacking. The development of new P2X7-specific nanobodies (nbs) has enabled us to effectively block the P2X7 channel. METHODS: Temporary middle cerebral artery occlusion (tMCAO) in wild-type (wt) and P2X7 transgenic (tg) mice was used to model ischemic stroke. Adenosine triphosphate (ATP) release was assessed in transgenic ATP sensor mice. Stroke size was measured after P2X7-specific nbs were injected intravenously (iv) and intracerebroventricularly (icv) directly before tMCAO surgery. In vitro cultured microglia were used to investigate calcium influx, pore formation via 4,6-diamidino-2-phenylindole (DAPI) uptake, caspase 1 activation and interleukin (IL)-1β release after incubation with the P2X7-specific nbs. RESULTS: Transgenic ATP sensor mice showed an increase in ATP release in the ischemic hemisphere compared to the contralateral hemisphere or the sham-treated mice up to 24 h after stroke. P2X7-overexpressing mice had a significantly greater stroke size 24 h after tMCAO surgery. In vitro experiments with primary microglial cells demonstrated that P2X7-specific nbs could inhibit ATP-triggered calcium influx and the formation of membrane pores, as measured by Fluo4 fluorescence or DAPI uptake. In microglia, we found lower caspase 1 activity and subsequently lower IL-1β release after P2X7-specific nb treatment. The intravenous injection of P2X7-specific nbs compared to isotype controls before tMCAO surgery did not result in a smaller stroke size. As demonstrated by fluorescence-activated cell sorting (FACS), after stroke, iv injected nbs bound to brain-infiltrated macrophages but not to brain resident microglia, indicating insufficient crossing of the blood–brain barrier of the nbs. Therefore, we directly icv injected the P2X7-specific nbs or the isotype nbs. After icv injection of 30 µg of P2X7 specific nbs, P2X7 specific nbs bound sufficiently to microglia and reduced stroke size. CONCLUSION: Mechanistically, we can show that there is a substantial increase of ATP locally after stroke and that blockage of the ATP receptor P2X7 by icv injected P2X7-specific nbs can reduce ischemic tissue damage. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02601-z.
format Online
Article
Text
id pubmed-9559872
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95598722022-10-14 Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions Wilmes, Maximilian Pinto Espinoza, Carolina Ludewig, Peter Stabernack, Joschi Liesz, Arthur Nicke, Annette Gelderblom, Mathias Gerloff, Christian Falzoni, Simonetta Tolosa, Eva Di Virgilio, Francesco Rissiek, Björn Plesnilla, Nikolaus Koch-Nolte, Friedrich Magnus, Tim J Neuroinflammation Research BACKGROUND: Previous studies have demonstrated that purinergic receptors could be therapeutic targets to modulate the inflammatory response in multiple models of brain diseases. However, tools for the selective and efficient targeting of these receptors are lacking. The development of new P2X7-specific nanobodies (nbs) has enabled us to effectively block the P2X7 channel. METHODS: Temporary middle cerebral artery occlusion (tMCAO) in wild-type (wt) and P2X7 transgenic (tg) mice was used to model ischemic stroke. Adenosine triphosphate (ATP) release was assessed in transgenic ATP sensor mice. Stroke size was measured after P2X7-specific nbs were injected intravenously (iv) and intracerebroventricularly (icv) directly before tMCAO surgery. In vitro cultured microglia were used to investigate calcium influx, pore formation via 4,6-diamidino-2-phenylindole (DAPI) uptake, caspase 1 activation and interleukin (IL)-1β release after incubation with the P2X7-specific nbs. RESULTS: Transgenic ATP sensor mice showed an increase in ATP release in the ischemic hemisphere compared to the contralateral hemisphere or the sham-treated mice up to 24 h after stroke. P2X7-overexpressing mice had a significantly greater stroke size 24 h after tMCAO surgery. In vitro experiments with primary microglial cells demonstrated that P2X7-specific nbs could inhibit ATP-triggered calcium influx and the formation of membrane pores, as measured by Fluo4 fluorescence or DAPI uptake. In microglia, we found lower caspase 1 activity and subsequently lower IL-1β release after P2X7-specific nb treatment. The intravenous injection of P2X7-specific nbs compared to isotype controls before tMCAO surgery did not result in a smaller stroke size. As demonstrated by fluorescence-activated cell sorting (FACS), after stroke, iv injected nbs bound to brain-infiltrated macrophages but not to brain resident microglia, indicating insufficient crossing of the blood–brain barrier of the nbs. Therefore, we directly icv injected the P2X7-specific nbs or the isotype nbs. After icv injection of 30 µg of P2X7 specific nbs, P2X7 specific nbs bound sufficiently to microglia and reduced stroke size. CONCLUSION: Mechanistically, we can show that there is a substantial increase of ATP locally after stroke and that blockage of the ATP receptor P2X7 by icv injected P2X7-specific nbs can reduce ischemic tissue damage. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02601-z. BioMed Central 2022-10-12 /pmc/articles/PMC9559872/ /pubmed/36224611 http://dx.doi.org/10.1186/s12974-022-02601-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wilmes, Maximilian
Pinto Espinoza, Carolina
Ludewig, Peter
Stabernack, Joschi
Liesz, Arthur
Nicke, Annette
Gelderblom, Mathias
Gerloff, Christian
Falzoni, Simonetta
Tolosa, Eva
Di Virgilio, Francesco
Rissiek, Björn
Plesnilla, Nikolaus
Koch-Nolte, Friedrich
Magnus, Tim
Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions
title Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions
title_full Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions
title_fullStr Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions
title_full_unstemmed Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions
title_short Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions
title_sort blocking p2x7 by intracerebroventricular injection of p2x7-specific nanobodies reduces stroke lesions
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559872/
https://www.ncbi.nlm.nih.gov/pubmed/36224611
http://dx.doi.org/10.1186/s12974-022-02601-z
work_keys_str_mv AT wilmesmaximilian blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT pintoespinozacarolina blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT ludewigpeter blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT stabernackjoschi blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT lieszarthur blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT nickeannette blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT gelderblommathias blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT gerloffchristian blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT falzonisimonetta blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT tolosaeva blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT divirgiliofrancesco blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT rissiekbjorn blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT plesnillanikolaus blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT kochnoltefriedrich blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions
AT magnustim blockingp2x7byintracerebroventricularinjectionofp2x7specificnanobodiesreducesstrokelesions